Ultragenyx Pharmaceutical Inc. Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 136.0M | 207.0M | 159.9M | 166.5M | 139.3M | 164.9M | 139.5M | 147.0M |
| Cost of Goods Sold | 30.0M | 29.0M | 28.0M | 23.0M | 28.7M | 16.9M | 21.0M | 21.3M |
| Gross Profit | 106.0M | 178.0M | 131.9M | 143.5M | 110.6M | 148.0M | 118.5M | 125.7M |
| R&D Expenses | 187.0M | 203.0M | 216.2M | 164.7M | 165.8M | 187.8M | 170.1M | 161.5M |
| Operating Expenses | 275.0M | 292.0M | 302.8M | 251.4M | 253.6M | 270.3M | 250.5M | 242.1M |
| Operating Income | -169.0M | -114.0M | -170.9M | -107.9M | -142.9M | -122.3M | -132.0M | -116.4M |
| Other Income / Gains | -15.0M | -14.0M | -8.7M | -6.1M | -6.8M | -11.1M | -1.2M | -14.4M |
| Net Income | -185.0M | -129.0M | -180.4M | -115.0M | -151.1M | -133.4M | -133.5M | -131.6M |
| EPS (Diluted) | -1.84 | -1.29 | -1.81 | -1.17 | -1.57 | -1.39 | -1.40 | -1.52 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | 0.779 | 0.86 | 0.825 | 0.862 | 0.794 | 0.898 | 0.849 | 0.855 |
| General And Administrative Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 88.0M | 89.0M | 86.6M | 86.6M | 87.8M | 82.5M | 80.4M | 80.6M |
| Other Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost And Expenses | 305.0M | 321.0M | 330.8M | 274.4M | 282.2M | 287.2M | 271.5M | 263.4M |
| Interest Income | 6.0M | 6.5M | 5.9M | 5.8M | 6.8M | 9.6M | 10.7M | 7.4M |
| Interest Expense | 21.0M | 19.0M | 14.1M | 14.0M | 14.3M | 15.5M | 15.7M | 16.0M |
| Depreciation And Amortization | 8.0M | 8.8M | 8.6M | 8.6M | 9.0M | 9.1M | 8.8M | 8.9M |
| Ebitda | -155.0M | -100.2M | -156.8M | -91.3M | -126.4M | -108.8M | -108.7M | -105.9M |
| Ebitdaratio | -1.14 | -0.484 | -0.98 | -0.549 | -0.908 | -0.66 | -0.78 | -0.72 |
| Operating Income Ratio | -1.243 | -0.551 | -1.069 | -0.648 | -1.026 | -0.742 | -0.946 | -0.791 |
| Income Before Tax | -184.0M | -128.0M | -179.5M | -114.0M | -149.8M | -133.4M | -133.2M | -130.7M |
| Income Before Tax Ratio | -1.353 | -0.618 | -1.123 | -0.685 | -1.075 | -0.809 | -0.955 | -0.889 |
| Income Tax Expense | 1.0M | 1.0M | 873K | 947K | 1.3M | -19K | 303K | 858K |
| Net Income Ratio | -1.36 | -0.623 | -1.128 | -0.69 | -1.085 | -0.809 | -0.957 | -0.895 |
| Epsdiluted | -1.84 | -1.29 | -1.81 | -1.17 | -1.57 | -1.39 | -1.40 | -1.52 |
| Weighted Average Shs Out | 100.6M | 99.9M | 99.8M | 98.5M | 96.3M | 95.7M | 95.5M | 86.6M |
| Weighted Average Shs Out Dil | 100.6M | 99.9M | 99.8M | 98.5M | 96.3M | 95.7M | 95.5M | 86.6M |